GlassScriptPrepare for your visit
Vidhya Subramanian
Endocrinology, Diabetes & Metabolism · Katy, TX · NPI 1295752004
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$12,920.63
in general payments reported to CMS, 2019-2025 · $4,842 in 2025
The $4,842 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Who reported paying
General payments only, top 6 by amount.
- Novo Nordisk INC $1,348.16
- Lilly USA, LLC $1,244.75
- Amgen INC. $1,075.50
- Mannkind Corporation $680.26
- Insulet Corporation $600.69
- Sanofi-Aventis U.S. LLC $586.28
Drugs and devices associated with these payments
Jardiance Afrezza Ilet Bionic Pancreas Omnipod Ozempic Dexcom G6 Transmitter Evenity Wegovy Mounjaro Kerendia Prolia Tymlos
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Vidhya Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/57972/vidhya-subramanian